Study Confirms Excellent Prognosis for Stage I Seminoma
the Cancer Therapy Advisor take:
Patients presenting with stage I seminoma who received a single cycle of adjuvant carboplatin following inguinal orchidectomy have an excellent prognosis, a new study published online ahead of print in the journal Annals of Oncology has shown.
For the retrospective analysis, researchers identified 517 patients with stage I testicular seminomatous germ cell tumor who received one cycle of adjuvant carboplatin South Central England between 1996 and 2013.
Results showed that with a median follow-up of 47.2 months, the 5-year estimated relapse-free survival was 95.0% (95% CI: 92.8, 97.3). In the 21 patients that relapsed, the median time to relapse was 22.7 months. Only four patients experienced a relapse beyond 3 years and 95% of relapsed patients had retroperitoneal lymph node metastases.
Researchers found that 76% of those that relapsed had elevated tumor markers at the time of relapse. Nearly 4% of all patients developed a new contralateral testicular germ cell cancer.
The findings suggest that increasing tumor size is associated with an increased risk of post-chemotherapy relapse.
Patients presenting with stage I seminoma who received adjuvant carboplatin following inguinal orchidectomy have excellent prognosis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer